Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: A model-based...

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Relapsed/refractory diffuse large B-cell lymphoma (r/rDLBCL) presents a significant challenge due to limited effective treatment options.
• Recent advancements have introduced novel therapies, necessitating a quantitative comparison of their efficacy.
• No prior comprehensive meta-analyses have systematically evaluated and compared the efficacy of emerging r/rDLBCL treatments.

Approach:

• A model-based meta-analysis was conducted to compare the efficacy of 11 treatment strategies and 63 treatment regimens for r/rDLBCL.
• Key efficacy endpoints analyzed included overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
• Quantitative comparisons were performed to identify superior treatment approaches and specific regimens.

Key Points:

• Combination therapies demonstrated significant benefits in OS, PFS, and ORR compared to monotherapy in r/rDLBCL.
• Chemotherapy-based regimens improved ORR and PFS, but not OS.
• Identified top-performing strategies include chemotherapy with immunotherapy followed by ASCT, dual immunotherapy, and chemotherapy followed by ASCT.

Conclusions:

• Specific high-efficacy regimens for r/rDLBCL include rituximab plus inotuzumab ozogamicin and R-BEAM+ASCT.
• A strong correlation exists between 6-month PFS and 2-year OS in combination therapies for r/rDLBCL.
• Findings provide crucial quantitative data to guide clinical practice and optimize clinical trial design for r/rDLBCL.